Nephroprotective Effects of Cardamonin on Renal Ischemia Reperfusion Injury/UUO-Induced Renal Fibrosis

Abstract

Acute kidney injury and chronic renal fibrosis are intractable pathological processes to resolve, yet limited strategies are able to effectively address them. Cardamonin (CAD) is a flavonoid with talented antioxidant, anti-inflammatory capacity, and satisfactory biosafety. In our study, animal and cellular models of renal ischemia/reperfusion (I/R) and unilateral ureteral obstruction (UUO) were successfully constructed to confirm whether CAD confers protective effects and underlying mechanisms. Animal experiments demonstrated that CAD application (100 mg/kg) distinctly ameliorated tissue damage and improved renal function. Meanwhile, the continuous oral administration of CAD after UUO surgery efficiently inhibited renal fibrosis as confirmed by hematoxylin−eosin (H&E), Sirius red, and Masson staining as well as the downregulated mRNA and protein expression of collagen I, α-smooth muscle actin (α-SMA), collagen III, and fibronectin. Interestingly, in transforming growth factor β1 (TGF-β1)stimulated and hypoxia/reoxygenation (H/R)-exposed human kidney-2 (HK-2) cells, protective effects of CAD were again authenticated. Meanwhile, we performed bioinformatics analysis and constructed the "ingredient−target−pathway−disease" network to conclude that the potential mechanisms of CAD protection may be through the regulation of oxidative stress, inflammation, apoptosis, and mitogen-activated protein kinase (MAPK) pathway. Furthermore, experimental data validated that CAD evidently decreased the reactive oxygen species (ROS) production and malondialdehyde (MDA) content while depressing the mRNA and protein expression of inflammatory markers (tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and Il-1β) and inhibiting apoptosis as evidenced by decreased levels of P53, BAX, cleaved caspase-3, and apoptotic rate in renal I/R and UUO models. In addition, the impact of CAD on restraining oxidative stress and inflammation was attributed to its ability to elevate antioxidant enzyme activities including catalase, superoxide dismutase 1 (SOD1), and superoxide dismutase 2 (SOD2) and to inhibit the inflammation-associated MARK/nuclear factor-κB (MAPK/NF-κB) signaling pathway. In conclusion, cardamonin restored the antioxidative capacity to block oxidative stress and suppressed the MAPK/NF-κB signaling pathway to alleviate inflammatory response, thus mitigating I/R-generated acute kidney injury/UUO-induced renal fibrosis in vivo and in vitro, which indicated the potential therapeutic advantage of cardamonin in attenuating acute and chronic kidney injuries.

ROS-responsive MSC-derived Exosome Mimetics Carrying MHY1485 Alleviate Renal Ischemia Reperfusion Injury through Multiple Mechanisms

“…TNF-α, a major contributor to the pathogenesis of IR in most tissues produced by a variety of cell types, induces the expression of chemokines and the production of ROS, promoting the recruitment and activation of immune cells in IR kidneys . IR-induced damage-associated molecular patterns and TNF-α enhance the expression of IL-1β and IL-6, upregulating adhesion molecules and promoting lymphocyte recruitment in IR areas . The miRNAs in MTM-EM, such as miR-1184 and miR-146b, are found to decrease the secretion of pro-inflammatory cytokines through regulation on NF-κB, Sirtuin-1, or IL-1 receptor-associated kinase signaling pathways, eventually mitigating immune responses in IR kidneys. − …”

“… 49 IR-induced damage-associated molecular patterns and TNF-α enhance the expression of IL-1β and IL-6, upregulating adhesion molecules and promoting lymphocyte recruitment in IR areas. 50 The miRNAs in MTM-EM, such as miR-1184 and miR-146b, are found to decrease the secretion of pro-inflammatory cytokines through regulation on NF-κB, Sirtuin-1, or IL-1 receptor-associated kinase signaling pathways, eventually mitigating immune responses in IR kidneys. 51 − 53 …”